By adding GET to the therapeutic plasmid, the effectiveness was significantly improved (37.3 days of tumor growth delay) in 50% of tumor-free mice, which is a significantly better outcome than that observed in previous studies by targeting either CD146 alone (28.7 days TGD and 26.7% CR) [33] or CD105 alone (15 days TGD and 40% CR) [29]. This evidence concerns the gene MCAM and neoplasm.